An emerging concept in MS research is the role of the lung microbiome in promoting disease severity, with preliminary evidence showing that pulmonary micro-organisms can regulate autoimmunity in the central nervous system (reviewed in Chen et al. Int J Mol Sci 2023;24:2170). Read More
Latest News
Neurofilament-light chain (NfL) as a biomarker of response to higher-efficacy disease-modifying therapies
November 22, 2023Includes data on NfL changes after initiation of fingolimod, ofatumumab, ocrelizumab, natalizumab, alemtuzumab and oral cladribine.
11 slides
OCT – diagnosis and prognosis
November 8, 2023ECTRIMS-ACTRIMS 2023 presented new data on the use of optical coherence tomography (OCT) as a biomarker in multiple sclerosis. The following is a brief summary of recent findings. Read More
Novel treatments: targeting CD40 ligand
November 1, 2023The transmembrane receptor CD40 and its ligand (CD40L or CD154) are involved in initiating and sustaining the inflammatory response. While these responses are beneficial in infection and tumour lysis, chronic activation has been implicated in a range of neuroinflammatory and autoimmune conditions, including MS, Alzheimer’s disease and Parkinson’s disease. Read More